血管紧张素转换酶2作为COVID-19的治疗靶点
Angiotensin converting enzyme-2 as therapeutic target in COVID-19.
作者信息
Roshanravan Neda, Ghaffari Samad, Hedayati Mehdi
机构信息
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
出版信息
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):637-639. doi: 10.1016/j.dsx.2020.05.022. Epub 2020 May 12.
Abstract
The pandemic of coronavirus disease 2019 (COVID-19) is a global health emergency that poses a significant threat to world people's health. This outbreak causes major challenges to healthcare systems. Given the lack of effective treatments or vaccine for it, the identification of novel and safe drugs against COVID-19 infection is an urgent need. Angiotensin-converting enzyme 2 (ACE2) is not only an entry receptor of the SARS-CoV-2 virus, the virus that causes COVID-19, but also can protect from lung injury. In this view, we highlighted potential approaches to address ACE2-mediated SARS-CoV-2 virus, including 1) delivering an excessive soluble form of ACE2 (recombinant human ACE2: rhACE2) and 2) inhibition of the interaction between SARS-CoV-2 virus and ACE2 by some compounds with competitive effects (morphine and codeine). Further clinical trials in this regard can reveal a more definite conclusion against the COVID-19 disaster.
摘要
2019年冠状病毒病（COVID-19）大流行是一场全球卫生突发事件，对世界人民的健康构成重大威胁。此次疫情给医疗系统带来了巨大挑战。鉴于缺乏针对该疾病的有效治疗方法或疫苗，鉴定出新型且安全的抗COVID-19感染药物迫在眉睫。血管紧张素转换酶2（ACE2）不仅是导致COVID-19的SARS-CoV-2病毒的进入受体，还能保护免受肺损伤。基于此观点，我们重点介绍了应对ACE2介导的SARS-CoV-2病毒的潜在方法，包括1）递送过量的可溶性ACE2形式（重组人ACE2：rhACE2）以及2）通过一些具有竞争作用的化合物（吗啡和可待因）抑制SARS-CoV-2病毒与ACE2之间的相互作用。在这方面的进一步临床试验可以针对COVID-19灾难揭示更明确的结论。
相似文献
1
Angiotensin converting enzyme-2 as therapeutic target in COVID-19.血管紧张素转换酶2作为COVID-19的治疗靶点
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):637-639. doi: 10.1016/j.dsx.2020.05.022. Epub 2020 May 12.
2
Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.血管紧张素转换酶 2 的器官保护作用及其对 COVID-19 预后的影响。
J Med Virol. 2020 Jul;92(7):726-730. doi: 10.1002/jmv.25785. Epub 2020 Apr 5.
3
ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.ACE2，肾脏与 ACE2 发现二十年后的 COVID-19 。
Clin Sci (Lond). 2020 Nov 13;134(21):2791-2805. doi: 10.1042/CS20200484.
4
Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19.新冠病毒 2 型受体（SARS-CoV-2 receptor），血管紧张素转换酶 2 基因（angiotensin-converting enzyme 2 gene）在 COVID-19 中的表达和意义。
Mol Biol Rep. 2020 Jun;47(6):4383-4392. doi: 10.1007/s11033-020-05478-4. Epub 2020 May 14.
5
A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.维生素 D 与血管紧张素转换酶 2 相互作用的简要综述：COVID-19 潜在治疗方法的启示。
Rev Med Virol. 2020 Sep;30(5):e2119. doi: 10.1002/rmv.2119. Epub 2020 Jun 25.
6
ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.ACE2 和 ACE：基于结构的 SARS-CoV 机制、调控和受体识别的见解。
Clin Sci (Lond). 2020 Nov 13;134(21):2851-2871. doi: 10.1042/CS20200899.
7
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.JAK 抑制作为 COVID-19 患者的一种新治疗策略。
Int Arch Allergy Immunol. 2020;181(6):467-475. doi: 10.1159/000508247. Epub 2020 May 11.
8
Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.ACE2 调节的内分泌方面：肾素-血管紧张素-醛固酮系统、类固醇激素和 SARS-CoV-2。
J Endocrinol. 2020 Nov;247(2):R45-R62. doi: 10.1530/JOE-20-0260.
9
Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).新型冠状病毒病 2019（COVID-19）与肾素-血管紧张素系统：深入了解血管紧张素转换酶 2（ACE2）。
Ann Clin Biochem. 2020 Sep;57(5):339-350. doi: 10.1177/0004563220928361. Epub 2020 Jun 2.
10
Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.新冠病毒刺突蛋白与人血管紧张素转化酶 2 协同结合和信号转导的共进化、动力学和变构协同作用。
Int J Mol Sci. 2020 Nov 4;21(21):8268. doi: 10.3390/ijms21218268.
引用本文的文献
1
Management of critically Ill COVID-19 patients: Exploring the potential of morphine and assessing disadvantages of acetaminophen.危重型新冠肺炎患者的管理：探索吗啡的潜在作用并评估对乙酰氨基酚的弊端
Caspian J Intern Med. 2025 Mar 17;16(2):381-383. doi: 10.22088/cjim.16.2.381. eCollection 2025 Spring.
2
Correlation between bioactive lipids and novel coronavirus: constructive role of biolipids in curbing infectivity by enveloped viruses, centralizing on EPA and DHA.生物活性脂质与新型冠状病毒之间的相关性：生物脂质在抑制包膜病毒感染性方面的建设性作用，重点关注二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）。
Syst Microbiol Biomanuf. 2021;1(2):186-192. doi: 10.1007/s43393-020-00019-3. Epub 2021 Feb 3.
3
Possible therapeutic targets for SARS-CoV-2 infection and COVID-19.新型冠状病毒（SARS-CoV-2）感染及新冠肺炎（COVID-19）可能的治疗靶点。
J Allergy Infect Dis. 2021;2(3):75-83. doi: 10.46439/allergy.2.028.
4
Ketogenic Diet and Ketone Bodies as Clinical Support for the Treatment of SARS-CoV-2-Review of the Evidence.生酮饮食和酮体作为治疗 SARS-CoV-2 的临床支持——证据回顾。
Viruses. 2023 May 27;15(6):1262. doi: 10.3390/v15061262.
5
Importance of ACE2 for SARS-CoV-2 Infection of Kidney Cells.ACE2 对 SARS-CoV-2 感染肾细胞的重要性。
Biomolecules. 2023 Mar 3;13(3):472. doi: 10.3390/biom13030472.
6
Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review.与 COVID-19 感染及相关细胞因子风暴相关的表观遗传学观点：最新综述。
Infection. 2023 Dec;51(6):1603-1618. doi: 10.1007/s15010-023-02017-8. Epub 2023 Mar 12.
7
S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进入细胞及感染性过程中的刺突蛋白（S蛋白）、血管紧张素转换酶2（ACE2）和宿主细胞蛋白酶；可溶性ACE2是双刃剑吗？一篇综述
Vaccines (Basel). 2023 Jan 17;11(2):204. doi: 10.3390/vaccines11020204.
8
Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.肺部药物递送：抗击 COVID-19 的有效且便捷的给药途径。
Drug Deliv Transl Res. 2023 Mar;13(3):705-715. doi: 10.1007/s13346-022-01251-1. Epub 2022 Oct 19.
9
Andrographolide induces anti-SARS-CoV-2 response through host-directed mechanism: an study.穿心莲内酯通过宿主导向机制诱导抗SARS-CoV-2反应：一项研究。
Future Virol. 2022 Jun. doi: 10.2217/fvl-2021-0171. Epub 2022 Jul 4.
10
Opioid-Use, COVID-19 Infection, and Their Neurological Implications.阿片类药物使用、2019冠状病毒病感染及其神经学影响
Front Neurol. 2022 May 23;13:884216. doi: 10.3389/fneur.2022.884216. eCollection 2022.
本文引用的文献
1
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
2
Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19.油酰乙醇酰胺，一种生物活性脂质酰胺，作为一种有前途的冠状病毒/COVID-19 治疗策略。
Arch Med Res. 2020 Jul;51(5):464-467. doi: 10.1016/j.arcmed.2020.04.006. Epub 2020 Apr 15.
3
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.在新冠疫情期间，血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂可能对糖尿病患者有害。
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):349-350. doi: 10.1016/j.dsx.2020.04.019. Epub 2020 Apr 15.
4
The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis.2019 新型冠状病毒对心脏损伤的影响：系统评价和荟萃分析。
Prog Cardiovasc Dis. 2020 Jul-Aug;63(4):518-524. doi: 10.1016/j.pcad.2020.04.008. Epub 2020 Apr 16.
5
[Palliation in patients with severe COVID-19].[重症新型冠状病毒肺炎患者的姑息治疗]
Lakartidningen. 2020 Apr 3;117:F3PM.
6
The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease.2019 年冠状病毒病（COVID-19）的心血管负担，重点关注先天性心脏病。
Int J Cardiol. 2020 Jun 15;309:70-77. doi: 10.1016/j.ijcard.2020.03.063. Epub 2020 Mar 28.
7
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.2019冠状病毒病（COVID-19）与心血管疾病：关于血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的发病和严重程度潜在影响的观点
J Am Heart Assoc. 2020 Apr 7;9(7):e016219. doi: 10.1161/JAHA.120.016219. Epub 2020 Apr 1.
8
A Genomic Perspective on the Origin and Emergence of SARS-CoV-2.从基因组角度看 SARS-CoV-2 的起源与出现。
Cell. 2020 Apr 16;181(2):223-227. doi: 10.1016/j.cell.2020.03.035. Epub 2020 Mar 26.
9
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
10
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
Zotero 插件